MedPage Today broadens its scope

Share this article:
Ivan Oransky
Ivan Oransky

MedPage Today's new VP and global editorial director, Ivan Oransky, has a goal in mind: to make the resource even more top-of-mind among the medical community by broadening and deepening its content and engagement. “We already are global...going more global is a serious undertaking,” says Oransky, who came over from Reuters Health, where he was executive editor.

Oransky, whose experience also includes co-founding the blog Retraction Watch and founding Embargo Watch, as well as stints at Scientific American and the Scientist, tells MM&M that the key to helping MedPage reach its goals is the audience. He plans on enriching MedPage's universe by bringing professionals into the conversation.

This means recruiting and elevating bloggers who are “already out there, but haven't gotten attention.” Oransky says a strong blog network lets professionals “talk among themselves. That's to me, a big sort of gap and a great opportunity.”

But tapping into the everyday voice does not mean moving MedPage to a crowd-sourced news model. Oransky says MedPage will still cover news, but the new voices will mean the site has “more boots on the ground.”

In addition to blogs, Oransky foresees creating a white-list moderated commenting model, which bases its scrutiny of a writer's remarks on past experience: writers who establish themselves as balanced and provocative will be able to post with a limited amount of editorial supervision.

Oransky also anticipates leveraging current assets to a greater degree. He says he wants to do more with contributor Sanjay Gupta, because “he has such a great expertise.” He also envisions newsletters and more relationships with medical societies.

He says he expects to have the beginnings of the new effort in place by mid-fall, as medical conference season hits. The build-out has already started.

Retraction Watch and Embargo Watch will go on. But he stresses that MedPage will come first, saying both Watches must “take a back seat to my real passion, which is of course medical news, healthcare news...building a tremendous community.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?